Rinvoq OverviewUpadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated. It was approved for medical use in the United States and in the European Union in 2019, and was developed by the biotech company AbbVie. Commo...
Read more Rinvoq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Upadacitinib
Recent Rinvoq Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet, Extended Release: 15mg
NDC Database Records for Rinvoq: (1 result)Sorted by National Drug Code
- 0074-2306 Rinvoq 15 mg Oral Tablet, Extended Release by Abbvie Inc.